Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20948546 
Shimada M, et al. (2010) Protein phosphatase 1γ is responsible for dephosphorylation of histone H3 at Thr 11 after DNA damage. EMBO Rep 11, 883-9 20948546
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T12-p - H3 (human)
Orthologous residues
H3 (human): T12‑p, H3 (mouse): T12‑p, H3 iso2 (mouse): T12‑p, H3 iso3 (mouse): T12‑p, H3 (rat): T12‑p, H3 iso3 (rat): T12‑p, H3 (pig): T12‑p, H3 (chicken): T12‑p, H3 (cow): T12‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  HCT116 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP1CC (human) phospho-antibody, inhibition of upstream enzyme, siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV decrease
okadaic acid UV inhibit treatment-induced decrease
RO-3306 UV augment treatment-induced decrease
fostriecin UV no effect upon treatment-induced decrease
caffeine UV inhibit treatment-induced decrease
UV ATR (human) decrease ATR siRNA inhibits decrease
purvalanol decrease
CDK1 (human) increase CDK1 siRNA decreases
CDK2 (human) increase CDK2 siRNA decreases
Downstream Regulation
 Effect of modification (process):  cell cycle regulation, transcription, altered

T311-p - PPP1CC (human)
Orthologous residues
PPP1CC (human): T311‑p, PPP1CC iso2 (human): T311‑p, PPP1CC (mouse): T311‑p, PPP1CC iso2 (mouse): T311‑p, PPP1CC (rat): T311‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  HCT116 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV decrease
caffeine UV inhibit treatment-induced decrease
UV ATR (human) decrease ATR siRNA inhibits decrease
purvalanol UV augment treatment-induced decrease
CDK1 (human) increase CDK1 siRNA decreases, overexpression increases
CDK2 (human) increase CDK2 siRNA decreases
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.